12 completed, 1 active not recruiting, 1 terminated. 6 Phase 3, 3 Phase 1, 3 Phase 4, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 5, Active not recruiting 1 |
| Phase 1 | 3 | Completed 3 |
| Phase 4 | 3 | Completed 3 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow trifarotene: new trials by email Literature Review of trifarotene trials Research Report on trifarotene
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris Trifarotene, Vehicle Cream - Acne Vulgaris | Phase 3 | Active not recruiting | Galderma R&D | 561 | 2025-09-23 | 2026-08-24 |
| A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris Trifarotene Cream 0.005%, AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG, AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT - Acne Vulgaris | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 1000 | 2024-06-20 | 2024-12-13 |
| A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris Trifarotene Cream 0.005%, Placebo, AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories) - Acne Vulgaris | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 762 | 2023-02-22 | 2023-10-02 |
| Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris Trifarotene 0.005 % Topical Cream, AKLIEF®, Placebo - Acne Vulgaris | Phase 3 | Completed | Teva Pharmaceuticals USA | 807 | 2022-09-19 | 2024-09-26 |
| AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation Trifarotene Cream, Trifarotene Vehicle Cream - Acne Vulgaris | Phase 4 | Completed | Galderma R&D | 123 | 2021-12-22 | 2023-12-20 |
| Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation Trifarotene Cream, Trifarotene Vehicle Cream - Acne Vulgaris | Phase 4 | Completed | Galderma R&D | 121 | 2021-05-28 | 2024-06-11 |
| A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV) Trifarotene cream, Doxycycline hyclate, Trifarotene Vehicle - Acne Vulgaris | Phase 4 | Completed | Galderma R&D | 202 | 2020-07-29 | 2022-05-10 |
| A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis CD5789 Cream 200 µg/g, CD5789 Cream 100 µg/g, CD5789 Cream Vehicle - Lamellar Ichthyosis | Phase 2 | Terminated | Mayne Pharma International Pty Ltd | 65 | 2019-05-01 | 2023-08-14 |
| Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris Trifarotene - Acne Vulgaris | Phase 3 | Completed | Galderma R&D | 47 | 2019-03-27 | 2021-12-15 |
| Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris CD5789 (trifarotene) 50μg/g cream, Placebo cream - Acne Vulgaris | Phase 3 | Completed | Galderma R&D | 1208 | 2015-11-30 | 2019-11-12 |
| Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris CD5789 (trifarotene) 50µg/g Cream, Placebo Cream - Acne Vulgaris | Phase 3 | Completed | Galderma R&D | 1212 | 2015-11-01 | 2019-11-12 |
| CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris CD5789 (trifarotene) - Acne Vulgaris | Phase 3 | Completed | Galderma R&D | 453 | 2015-02-23 | 2019-11-14 |
| CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL) CD5789 0.01% Cream - Lymphoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 11 | 2013-02-01 | 2016-04-13 |
| Dose Range Study of CD5789 in Acne Vulgaris CD5789 25 µg/g cream, CD5789 50 µg/g cream, CD5789 100 µg/g cream - Acne Vulgaris | Phase 2 | Completed | Galderma R&D | 304 | 2012-06-20 | 2021-09-20 |
Acne Vulgaris (12) · Facies (1) · Ichthyosis, Lamellar (1) · Lymphoma (1)
Galderma R&D (9) · Sun Pharmaceutical Industries, Inc. (2) · M.D. Anderson Cancer Center (1) · Mayne Pharma International Pty Ltd (1) · Teva Pharmaceuticals USA (1)
United States (13) · Canada (3) · Germany (3) · Hungary (3) · Spain (3) · Czechia (2) · France (2) · Puerto Rico (2) · Ukraine (2) · Australia (1) · China (1) · Israel (1) · Poland (1) · Romania (1) · Russia (1)
Kevin Chan (2) · Natalie Yantovskiy (2) · Jerry Tan, MD (1) · Keith A. Choate, MD (1) · Madeleine Duvic, MD (1) · Michael Graeber, M.D. (1) · Ulrike Blume-Peytavi, MD (1)